DEEP DIVE

BPC-157

What is BPC 157?

BPC-157 is a research peptide made of 15 amino acids, the building blocks of proteins. Its name means Body Protection Compound-157. Most findings come from cell and animal studies, not large human trials.

Last updated: 2026-10-08

At a Glance

Full Name: Body Protection Compound-157

Class: Stable gastric pentadecapeptide

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids)

Molecular Weight: 1,419.53 Da

CAS Number: 137525-51-0

Origin: Isolated from human gastric juice (BPC)

Stability: Stable in gastric acid (unique among peptides)

Primary Pathways: NO system, FAK-paxillin, VEGF, growth factor modulation

Preclinical Studies: 100+ published studies across multiple tissue types

Clinical Stage: Preclinical (extensive animal models); limited Phase 2 data (IBD)

IN THIS ARTICLE

Why is BPC-157 studied?How does BPC-157 work in research models?What does the evidence show?BPC-157 vs. Other Recovery & Healing Peptides What are the limits of the safety evidence?What questions remain for future research?FAQ References

Why is BPC-157 studied?

BPC-157 research focuses on tissue injury and repair. Published animal work includes tendon, ligament, muscle, gut, nerve and bone models. A result in one model does not establish the same effect in another.

The peptide is discussed in the literature as a stable gastric pentadecapeptide. Gastric means related to the stomach. Pentadecapeptide means a chain of 15 amino acids.

The cited 2025 reviews describe a large body of preclinical work. Preclinical means research before definitive human trials, often in cells or animals. These reviews also highlight the shortage of large, published human studies.

This distinction matters when reading claims about healing. An animal experiment can identify a research question. It cannot establish that a research vial treats an injury in a person.

How does BPC-157 work in research models?

BPC-157 is studied across several signaling pathways rather than one clearly defined receptor. A pathway is a series of changes inside or between cells. This makes its mechanism harder to isolate.

One focus is nitric oxide, or NO. This signaling molecule helps regulate blood vessel width and tissue responses. The cited reviews discuss how BPC-157 may affect NO in different experimental settings.

Other work examines VEGF, a signal linked to new blood vessel growth. Researchers also study FAK and paxillin, proteins involved in cell movement and attachment. These findings describe possible mechanisms, not proven treatments.

BPC-157's Multi-Pathway Healing Cascade

NO System Modulation

Researchers study changes in nitric oxide signaling. The reported response varies by tissue and injury model.

Angiogenesis & VEGF Upregulation

VEGF is a signal linked to blood vessel growth. Studies examine whether its activity changes in damaged tissue.

FAK-Paxillin Pathway Activation

FAK and paxillin help cells move and attach to surrounding material. Experiments examine these responses during repair.

Growth Factor Modulation

Growth factors are signals involved in cell growth and repair. Studies examine changes in their receptors and related responses.

Anti-Inflammatory & Cytoprotective Effects

Cytoprotection means protection of cells from damage. Animal and cell studies examine inflammatory signals and oxidative stress.

Neurotransmitter System Interaction

Neurotransmitters are chemical signals used by nerve cells. The cited review discusses several signaling systems in experimental models.

What does the evidence show?

The findings below come mainly from preclinical injury models. Each uses a defined tissue, species and outcome. Controls show whether the measured response differs under those conditions.

Tendon strength, cell movement and wound closure are different measurements. None should be treated as a substitute for human recovery. Read the cited source alongside each finding.

Tendon & Ligament Healing

Accelerated healing of transected Achilles tendons, MCL, and rotator cuff injuries in rat models. BPC-157-treated tendons showed superior biomechanical properties, increased collagen organization, and faster functional recovery compared to controls.

Staresinic et al., J Orthop Res, 2003; Cerovecki et al., J Orthop Surg Res, 2010

Muscle Injury Repair

Significantly accelerated healing of crushed and transected skeletal muscles. BPC-157 promoted myogenesis (new muscle fiber formation), reduced fibrosis, and restored contractile function faster than controls.

Novinscak et al., Regul Pept, 2008

Gastrointestinal Protection

Protected against gastric ulcers induced by NSAIDs, alcohol, restraint stress, and cysteamine across dozens of studies. BPC-157 also accelerated healing of existing ulcers, intestinal anastomosis, and inflammatory bowel disease models (both DSS and TNBS).

Sikiric et al., multiple publications 1993-2025

Peripheral Nerve Regeneration

Enhanced recovery of transected sciatic nerves, including faster axonal regrowth, improved nerve conduction velocity, and superior functional recovery (toe-spreading reflex) compared to controls.

Gjurasin et al., Regul Pept, 2010; Lazaridis et al., 2023

Bone Healing

Accelerated healing of segmental bone defects and pseudoarthrosis (non-union fractures). BPC-157-treated defects showed enhanced osteoblast activity, increased bone mineral density, and faster bridging of bone gaps.

Sebecic et al., J Bone Miner Metab, 1999

Traumatic Brain Injury

Reduced brain edema, improved neurological outcomes, and decreased mortality in TBI models. BPC-157 appeared to exert neuroprotection through multiple pathways including NO modulation and blood-brain barrier stabilization.

Tudor et al., Regul Pept, 2010; Sikiric et al., 2024

BPC-157 vs. Other Recovery & Healing Peptides

BPC-157, thymosin beta-4, GHK-Cu and KPV are different research materials. Their reported pathways and study models also differ. The table is a literature overview, not a ranking of treatments.

TB-500 naming needs care. A supplied fragment is not automatically equivalent to full-length thymosin beta-4. Different mechanisms do not establish that a blend works better than its components.

Property	BPC-157	TB-500 (Thymosin β4)	GHK-Cu	KPV
Primary Action	Multi-system tissue repair	Actin regulation & cell migration	Extracellular matrix remodeling	NF-κB anti-inflammation
Size	15 amino acids (1,419 Da)	43 amino acids (4,921 Da)	Tripeptide + Cu²⁺ (403 Da)	3 amino acids (342 Da)
Oral Stability	Excellent (gastric-stable)	Poor	Poor	Good (PepT1-mediated)
Tissue Breadth	Widest (gut, tendon, muscle, nerve, bone, brain)	Broad (muscle, cardiac, dermal)	Moderate (skin, hair, systemic)	Focused (gut, skin)
Mechanism	NO system + VEGF + FAK-paxillin	G-actin sequestration + cell migration	Copper delivery + gene modulation	NF-κB inhibition
Anti-Inflammatory	Moderate (secondary)	Moderate	Moderate (via copper)	Strong (primary)
Preclinical Depth	100+ studies	50+ studies	100+ studies	20+ studies
Key Advantage	Broadest healing evidence base	Cardiac & systemic repair	Gene expression breadth	Precision gut targeting
Frequently Stacked With	TB-500	BPC-157	BPC-157	BPC-157

What are the limits of the safety evidence?

The cited animal literature reports limited toxicity under the tested conditions. That does not establish safety in people. Rare effects and long-term risks require appropriate human evidence.

The 2025 narrative review highlights this gap. Neither a natural origin nor a lack of reported harm proves safety. This page provides research context, not personal treatment advice.

Acute Toxicity: No significant toxicity reported at any dose tested in preclinical models

Chronic Use: No adverse effects reported in extended administration protocols (up to 6 months in some studies)

Drug Interactions: Counteracts NSAID-induced gastropathy; interactions with NO-modulating drugs should be considered

Monitoring: Study-specific safety observations do not establish a personal-use protocol. Read the original source and its limitations.

What questions remain for future research?

The cited reviews discuss possible future work in tissue repair and related fields. These are research directions, not established clinical uses. Findings must be checked against the exact material and model.

BPC-157 is not an approved medicine for treating the injuries discussed here. Regulatory discussion is separate from whether an experimental finding is sound. This catalog supplies materials for laboratory research only.

Frequently Asked Questions

What is BPC-157?

How does BPC-157 work?

Research examines nitric oxide signaling, blood vessel growth and cell movement. Several pathways may be involved. The mechanism remains model-dependent.

What is the difference between BPC-157 and TB-500?

They are different research materials with different proposed mechanisms. TB-500 naming may refer to a fragment rather than full-length thymosin beta-4. Check identity before applying a study to a product.

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any indication. In 2023, the FDA added BPC-157 to its category 2 list of substances not eligible for compounding. It remains available for research purposes only.

What are the side effects of BPC-157?

Animal studies cannot establish the full risk in people. Large human safety trials are lacking. Rare and long-term effects remain uncertain.

How much does BPC-157 cost for research?

Current vial strengths and prices are shown in the product listing. Check available lot documents separately. A listing is not evidence of clinical efficacy.

References

[1] Sikiric P, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals. 2025;18(2):185.
[2] Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals. 2024;17(4):461.
[3] Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals. 2025;18(6):928.
[4] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18:611-619.
[5] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983.
[6] Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161.
[7] Seiwerth S, et al. BPC 157's effect on healing. J Physiol Paris. 1999;93(6):441-447.